Combination therapy before surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests giving a combination of immunotherapy, a growth factor to boost white blood cells, and chemotherapy before surgery for stomach cancer. The goal is to shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that has not spread to distant organs and is considered operable.
- Your cancer has not been treated with any prior systemic therapy (chemotherapy, radiation, etc.).
- You are generally in good health (able to do most daily activities, with adequate organ function).
- You do not have serious heart disease, bleeding disorders, or recent major blood clots.
- You have not had other cancers (except certain early-stage skin or cervical cancer) and no active infections like HIV, hepatitis B, or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
This trial tests whether giving a combination of chemotherapy and an immunotherapy drug before surgery helps shrink stomach cancer tumors and improve outcomes. The treatment is given in the neoadjuvant (before surgery) setting for stomach cancer that is locally advanced but not spread.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This trial tests a combination of chemotherapy drugs and an immunotherapy drug given before surgery for stomach cancer in younger patients. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new GC/GEJC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.